Johnson & Johnson soon to acquire Actelion

Johnson & Johnson and Actelion are negotiating an agreement under which the Swiss biotech would be acquired for $260 per share (13% premium) and its research center would remain independent. Actelion’s current shareholders could benefit from the deal. Specifically, this would create a new company whose main asset would be Actelion’s pipeline. The management of the new company, whose CEO could be Jean-Paul Clozel, is the only detail still being negotiated in these days.
(Source Reuters)